Are GLP-1s here for the long term, or will next-gen therapies soon be taking the limelight?
Regular monitoring ensures optimal dosing, safety, and visible results in skin clarity, energy, and overall wellness
doi: 10.1038/s41556-022-00934-8 83 LugininaAGusachALyapinaEKhornPSafronovaNShevtsovMet al
Likewise, energy metabolism and appetite regulation could be altered in a therapeutic direction ( The rationale for dual-receptor agonists for GLP-1 and GIP In healthy volunteers, infusions of GLP-1 and GIP had additive effects on the stimulation of insulin secretion ( In vitro receptor binding studies explored structural requirements for GLP-1 and GLP-1/GIP chimeric peptides regarding their affinity towards the GLP-1 receptor in insulinoma cell lines ( Figure 1 gives an overview of the physiological actions of GLP-1 and GIP on various organ systems ( Table 1 ( Figure 1 Table 1 Effects of GIP receptor agonism or antagonism on glycemic control, body weight, and energy balance in animal models of obesity and diabetes (modified according to Campbell and Nauck) ( Prevention of diet-induced obesity: healthy, nonobese animals at baseline receiving experimental treatment while receiving a high-fat diet

Medications such as Tirzepatide (Mounjaro/Zepbound) and Semaglutide (Ozempic/Wegovy) are transforming how we approach obesity and weight management across the United States